Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04958122 · ClinicalTrials.gov registry record · Phase 3
Cefixime Clinical Trial
A Phase 3 study of Human Immunodeficiency Virus and Syphilis, sponsored by University of Southern California.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT04958122 is a Phase 3 study of Human Immunodeficiency Virus and Syphilis that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 400 participants, above the 174-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (130% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04958122, a Phase 3 study of Human Immunodeficiency Virus and Syphilis, is actively recruiting participants, sponsored by University of Southern California.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to evaluate the efficacy of cefixime compared to benzathine penicillin G in the treatment of syphilis.
Conditions Studied
Interventions
- DRUG Cefixime 400mg
- DRUG benzathine penicillin
Study Locations (1)
California
- University of Southern California - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2021-06-20 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04958122
The ClinicalTrials.gov registry entry for NCT04958122 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 174-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (130% higher). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Human Immunodeficiency Virus appearing as the primary indexed condition, and to 2 interventions - of which Cefixime 400mg is the first listed.
NCT04958122 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04958122 about?
NCT04958122 is a clinical study titled "Cefixime Clinical Trial". This study aims to evaluate the efficacy of cefixime compared to benzathine penicillin G in the treatment of syphilis.
What is the current status of trial NCT04958122?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2021-06-20. Estimated completion is 2027-06-30.
What conditions does trial NCT04958122 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus, Syphilis.
What interventions are being tested in trial NCT04958122?
The interventions under investigation include: Cefixime 400mg (DRUG), benzathine penicillin (DRUG).
Who is sponsoring clinical trial NCT04958122?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04958122 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
Baricitinib for Reduction of HIV - CNS
RECRUITING · Phase 2
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
RECRUITING · Phase 2
-
Harm Reduction in HIV Primary Care for PLWH Who Use Drugs
RECRUITING
-
Tulane Abdominal Transplant Institute (TATI) of Solid Organ Transplantation of HIV-Positive Recipients From HIV-Positive Donors
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.